Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.62 |
| ▸ | FNTA | P49354 | 1/20 | 0.53 |
| ▸ | FNTB | P49356 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 7/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1371594 | 1.00 | S1PR1 (0.62) | S1PR1FNTAFNTBLTA4HFAAH | |
| SCHEMBL1372249 | 0.90 | S1PR1 (0.58) | S1PR1FNTAFNTBLTA4H | |
| SCHEMBL1372246 | 0.90 | S1PR1 (0.58) | S1PR1FNTAFNTBLTA4H | |
| SCHEMBL1372073 | 0.90 | S1PR1 (0.62) | S1PR1LTA4H | |
| SCHEMBL1372071 | 0.90 | S1PR1 (0.62) | S1PR1LTA4H | |
| SCHEMBL1373113 | 0.87 | MITF (0.51) | S1PR1LTA4H | |
| SCHEMBL1373110 | 0.87 | MITF (0.51) | S1PR1LTA4H | |
| SCHEMBL1373947 | 0.84 | LTA4H (0.56) | S1PR1LTA4H | |
| SCHEMBL1373748 | 0.84 | LTA4H (0.56) | S1PR1FNTAFNTBLTA4H | |
| SCHEMBL1373951 | 0.84 | LTA4H (0.56) | S1PR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| CN-102256944-A | Sphingosine-1-phosphate receptor antagonists | EXELIXIS INC | 2011-11-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885FNTA 1554/4885FNTB 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.